2021-10
Together with Kuntin Group, Everpine Capital established an industrial park fund to seek investment opportunities in the public Pre-REITs market
Couple days ago in September 2021, Everpine Capital and Kuntin Group have complete the fund-raising of Kuntin-Everpine Industrial Park Fund(hereinafter referred as the ‘Fund’), with the first phase of 300 million Chinese yuan and a total scale of 1 billion Chinese yuan. The fund aims to promote high-quality manufacturing industry, build characteristic industrial parks, promote industrial investment and add value to the industrial parks.
2019-08
UCP Glaucoma Surgery Technology Has Been Widely Recognized in The Ophthalmology Industry, Covering More Than 120 General Hospitals or Specialist Eye Care Hospitals in China
EyeOP1®, ETC’s product, was approved by CFDA in October 2017, and the company will focus on clinical and academic promotion in 2018. ETC actively promotes UCP technology and obtains support from authoritative professors at home and abroad.
2019-08
2019-08
The 2019 Summer Camp held by MacDuffie Shanghai and MIT Opens
The summer camp of underwater robots held by the Massachusetts institute of technology (MIT) and MacDuffie Shanghai opened on schedule in this hot summer. The events attacted over 130 students to engage in.
2019-05
2019-05
President of the MacDuffie School U.S. and Former MIT Admissions Officer Invite You to Attend the Campus Open Day ！
Principal of The MacDuffie School U.S., Steve Griffin visited the Shanghai branch to show how The MacDuffie School develops the student qualities favored by ivy league schools.
2019-08
Positively Recommending UCP Technology ! Domestic Top Glaucoma Experts, Professor Jian Ge and Xinghuai Sun, Positively Recommended The Pioneering Contribution of UCP Technology in The Treatment of Glaucoma
Professor Jian Ge from affiliated hospital of Sun Yat-Sen University Center, and Professor Xinghuai Sun from Eye Otolaryngology hospital affiliated to Fudan University recently mentioned in an interview that compared with traditional treatment of Glaucoma, UCP technology is more efficacy, faster postoperative recovery, small side effects, wide indications, completely noninvasive, easy operation, etc. It is groundbreaking to subvert traditional glaucoma therapy.
2019-05
Interview with Xiulong Yang, CEO of South Beauty and Chairman of the Beijing Parade: Home and Culture Are the Lasting Path of Enterprises
Interview with Xiulong Yang, CEO of South Beauty and Chairman of the Beijing Parade: Home and Culture Are the Lasting Path of Enterprises
2018-11
Interview with Experts on Eye Tech Care UCP Technology: Professor Chun Zhang and Professor Zhilan Yuan, the Earliest Clinical Users of UCP Technology in China
Prof. Chun Zhang and Prof. Zhilan Yuan are the earliest glaucoma experts who use UCP in clinic in China, and they have profound clinical experience on UCP. Based on their clinical experience, the two experts praised UCP for its features of efficient and stable lowering eye pressure, non-invasive, mild and safe, and simple operation. Compared with traditional glaucoma treatment technology (photocoagulation, surgery, etc.), UCP has an extraordinary advantage. It is believed that this technique is an innovative breakthrough in the treatment of glaucoma and will greatly promote the progress of clinical treatment of glaucoma.
2018-11
Interview with Expert on Eye Tech Care UCP Technology: Mr. Xinghuai Sun, Director of Department of Ophthalmology in Shanghai Medical College, Dean of Otolaryngology of Fudan University
Professor Xinghuai Sun is the professor of ophthalmology, chief physician and doctoral supervisor of eye, ear, nose and throat hospital affiliated to Fudan University. He is the founder of Shanghai Glaucoma Patient Club. He highly recommends and supports the pioneering contribution of UCP devices in the field of glaucoma treatment.
